Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-30 | June Almenoff, MD, PhD, has served as a director since February 2021. Dr. Almenoff is an accomplished biopharma executive with over 20 years of senior leadership experience. She served as President and Chief Medical Officer of Furiex Pharmaceuticals ("Furiex"), which was acquired by Actavis plc (now AbbVie) for $1.2B. |
| 2022-04-28 | June Almenoff, MD, PhD, has served as a director since February 2021. Our Board of Directors believes that Dr. Almenoff’s medical background and experience in drug development, commercial strategy, executive level leadership as well as her board experience on both public and private companies qualify her to serve on our Board. The Board has determined that Dr. Almenoff is an independent director. She serves on the Audit and Compliance Committee and the Corporate Governance and Nominating Committee. |
| 2023-04-28 | June Almenoff, MD, PhD has served as a director since February 2021. ... Our Board of Directors believes that Dr. Almenoff’s close to 25 years of leadership experience as a biopharma executive, her expertise in research and development, as well as her experience with public and private biotech boards, venture philanthropy investment, and product commercialization qualify her to serve on our Board. ... The members of the Audit and Compliance Committee are currently Drs. Almenoff and Davidson and Ms. Hunter. ... The members of the Corporate Governance and Nominating Committee are currently Drs. Almenoff and Doogan and Mr. Proehl. Dr. Almenoff serves as chair of the Corporate Governance and Nominating Committee. ... The following table summarizes the compensation paid to non-employee directors for fiscal year ended December 31, 2022: June Almenoff, MD, PhD 59,500 fees earned or paid in cash, 2,607 option awards, total 62,107. |
| 2023-10-27 | June Almenoff, MD, Phd 563 * |
| 2024-04-26 | June Almenoff, MD, PhD has served as a director since February 2021. Our Board of Directors believes that Dr. Almenoff’s close to 25 years of leadership experience as a biopharma executive, her expertise in research and development, as well as her experience with public and private biotech boards, venture philanthropy investment, and product commercialization qualify her to serve on our Board. The members of the Audit and Compliance Committee are currently Drs. Almenoff and Davidson and Ms. Hunter. The members of the Corporate Governance and Nominating Committee are currently Drs. Almenoff and Doogan and Mr. Proehl. The following table summarizes the compensation paid to non-employee directors for fiscal year ended December 31, 2023: June Almenoff, MD, PhD 59,500. |
| 2024-09-27 | June Almenoff, MD, PhD 59,500 |
Data sourced from SEC filings. Last updated: 2025-07-01